The effect of esketamine combined with sufentanil based patient-controlled intravenous analgesia for postoperative pain in patients undergoing third molar surgery and maxillofacial trauma: a randomized clinical trial DOI Creative Commons
Xue Li, Xin He, Mengya Li

et al.

BMC Oral Health, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 2, 2024

This study aims to investigate the effects of combining esketamine with sufentanil for postoperative patient-controlled intravenous analgesia (PCIA) in patients undergoing elective impacted tooth surgery or open reduction and internal fixation. In this single-center, prospective, double-blinded, randomized, parallel-controlled trial, 91 were randomly divided into two groups. The experimental group (group ES, n = 46) received a combination 1.5 µg/kg 1.0 mg/kg, while control S, 45) 2 alone PCIA after surgery. Primary outcome was assessed using Visual Analogue Scale (VAS) at rest during mouth opening 6 h, 12 24 48 h post-surgery. Secondary outcomes included Ramsay Sedation (RSS) scores, Quality Recovery-15 (QoR-15) patient satisfaction analgesia, occurrence adverse events within frequency button presses number requiring rescue also recorded. resting VAS scores mouth-opening post-surgery significantly lower Group ES than S (P < 0.05). Additionally, RSS higher 0.032) 0.021) ES. use decreased QoR-15 increased 0.001 P 0.001, respectively). incidences dizziness nausea/vomiting reduced 0.045 0.036, respectively) but one event nightmare observed. There no significant difference between combined third molar maxillofacial trauma can alleviate short-term pain, improve quality recovery. Esketamine is worth promoting clinical application oral retrospectively registered chictr.org.cn identifier: ChiCTR2400086662 on 08/07/2024.

Language: Английский

Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions DOI Creative Commons
Kenji Hashimoto, Mingming Zhao, Tingting Zhu

et al.

Journal of Anesthesia and Translational Medicine, Journal Year: 2024, Volume and Issue: 3(3), P. 65 - 75

Published: July 11, 2024

Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, similarly employed for anesthesia analgesia. The anesthetic effects of ketamine esketamine arise from their antagonism the N-methyl-D-aspartate receptor (NMDAR). In field psychiatry, rapid-acting antidepressant properties severe depression have generated significant interest, resulting its increased off-label usage United States (U.S.). 2019, nasal spray received approval use U.S. Europe. However, concerns emerged regarding potential adverse effects, including long-term efficacy, addiction risks, suicide risk clinical settings. contrast, arketamine, (R)-enantiomer ketamine, exhibits superior longer-lasting rodent models depression, with fewer side compared to esketamine. Nevertheless, research on efficacy safety arketamine patients remains limited. This article provides concise exploration historical two enantiomers while also delving into future directions application these fields.

Language: Английский

Citations

11
Special Issue on “Ketamine, MDMA, and Psychedelics in the Treatment of Neuropsychiatric Disorders” DOI
Kenji Hashimoto,

Xingming Wang,

Jichun Zhang

et al.

Asian Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 106, P. 104426 - 104426

Published: March 5, 2025

Language: Английский

Citations

0
S-Ketamine Reduces the Risk of Rebound Pain in Patients Following Total Knee Arthroplasty: A Randomized Controlled Trial DOI Creative Commons
Qun Li, Shaoqi Tian, Lei Zhang

et al.

Drug Design Development and Therapy, Journal Year: 2025, Volume and Issue: Volume 19, P. 2315 - 2327

Published: March 1, 2025

Investigating the effectiveness of S-ketamine in reducing rebound pain (RP) following total knee arthroplasty. This study was a randomized, double-blind, placebo-controlled trial involving 356 adult patients undergoing Patient enrollment occurred between April and October 2023, with in-person follow-up assessments conducted from admission to 3 days post-surgery. Participants were randomly assigned group (n = 178) placebo 178). In group, participants received continuous intraoperative infusion at dose 0.30 mg/(kg·h) completion spinal anesthesia until beginning joint cavity closure, whereas 0.9% saline same volume duration. The primary outcome incidence RP within 12 hours Secondary outcomes included 24 hours, time onset, first rescue analgesia, scores, opioid consumption, clinical outcomes, harms. observed 21.3% compared 34.8% post-surgery (adjusted RR, 0.62; 95% CI, 0.44 0.88; P 0.008). onset significantly delayed (unadjusted HR, 0.60; 0.41 0.009). numerical rating scale during activity physical therapy lower than (day 1 AM: unadjusted difference, -1; -1 0; 0.011; day PM: 0.003; therapy: -2; -2 < 0.001). quality recovery score higher 5; 5 satisfaction 1; effectively reduces risk delays its Additionally, can reduce early levels, enhance quality, improve patient satisfaction.

Language: Английский

Citations

0
PROPHYLACTIC KETAMINE: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS DOI
Astrid M. Cardona-Acosta, Lyonna F. Parise,

Carlos A. Bolaños‐Guzmán

et al.

Biological Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Development and validation of machine learning models for predicting post-cesarean pain and individualized pain management strategies: a multicenter study DOI Creative Commons

S. Lv,

Ning Sun, Chunhui Hao

et al.

BMC Anesthesiology, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 10, 2025

Effective management of postoperative pain remains a significant challenge in obstetric care due to the variability perception and response influenced by physical, medical, psychosocial factors. Current standardized protocols often fail accommodate this variability, necessitating more tailored approaches. This study aims improve following cesarean sections developing personalized using machine learning (ML) models. The analyzed efficacy eight ML models, including XGBoost, Random Forest, Neural Networks, data from two distinct hospital cohorts. Performance metrics such as Root Mean Squared Error (RMSE) Coefficient Determination (R²) were evaluated through internal external validations. SHAP value analysis was used identify key predictors influencing outcomes. XGBoost model demonstrated superior performance, achieving lowest RMSE highest R². Key factors impacting included esketamine use, anesthesia method, anesthetic drug type, with significantly delaying first activation patient-controlled intravenous analgesia (PCIA). highlights potential refine strategies care, suggesting that approaches, particularly incorporating specific methods, could enhance patient Not applicable.

Language: Английский

Citations

0
Effect of small dose esketamine on perioperative neurocognitive disorder and postoperative depressive symptoms in elderly patients undergoing major elective noncardiac surgery for malignant tumors: A randomized clinical trial DOI Creative Commons

Cuifang Huang,

Ruimin Yang,

Xianlong Xie

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(42), P. e40028 - e40028

Published: Oct. 18, 2024

Perioperative neurocognitive disorder and postoperative depressive symptoms are significant complications after surgery. Studies have indicated that esketamine possesses neuroprotective antidepressant qualities.

Language: Английский

Citations

2
The optimal esketamine dosage for perioperative depression: A meta-regression DOI
I‐Wen Chen,

Ting‐Sian Yu,

Kuo‐Chuan Hung

et al.

Asian Journal of Psychiatry, Journal Year: 2024, Volume and Issue: 97, P. 104075 - 104075

Published: May 24, 2024

Citations

1
The effect of esketamine combined with sufentanil based patient-controlled intravenous analgesia for postoperative pain in patients undergoing third molar surgery and maxillofacial trauma: a randomized clinical trial DOI Creative Commons
Xue Li, Xin He, Mengya Li

et al.

BMC Oral Health, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 2, 2024

This study aims to investigate the effects of combining esketamine with sufentanil for postoperative patient-controlled intravenous analgesia (PCIA) in patients undergoing elective impacted tooth surgery or open reduction and internal fixation. In this single-center, prospective, double-blinded, randomized, parallel-controlled trial, 91 were randomly divided into two groups. The experimental group (group ES, n = 46) received a combination 1.5 µg/kg 1.0 mg/kg, while control S, 45) 2 alone PCIA after surgery. Primary outcome was assessed using Visual Analogue Scale (VAS) at rest during mouth opening 6 h, 12 24 48 h post-surgery. Secondary outcomes included Ramsay Sedation (RSS) scores, Quality Recovery-15 (QoR-15) patient satisfaction analgesia, occurrence adverse events within frequency button presses number requiring rescue also recorded. resting VAS scores mouth-opening post-surgery significantly lower Group ES than S (P < 0.05). Additionally, RSS higher 0.032) 0.021) ES. use decreased QoR-15 increased 0.001 P 0.001, respectively). incidences dizziness nausea/vomiting reduced 0.045 0.036, respectively) but one event nightmare observed. There no significant difference between combined third molar maxillofacial trauma can alleviate short-term pain, improve quality recovery. Esketamine is worth promoting clinical application oral retrospectively registered chictr.org.cn identifier: ChiCTR2400086662 on 08/07/2024.

Language: Английский

Citations

1